Phathom Pharmaceuticals (NasdaqGS:PHAT) Q4 2025 Earnings call February 26, 2026 08:00 AM ET Company ParticipantsAnnabel Samimy - Managing Director of BioPharma and BiotechnologyAnthea Li - Senior Associate in Biotechnology Equity ResearchEric Sciorilli - Head of Investor RelationsLouise Chen - Managing DirectorMartin Auster - Managing DirectorMin Lee - Biotech Equity Research AssociateSanjeev Narula - Chief Financial and Business OfficerSteven Basta - President and CEOConference Call ParticipantsChase Knick ...

A $20 aspirin doesn't happen by accident. It happens by design. Mark Cuban, billionaire entrepreneur and co-founder of Cost Plus Drugs, is not new to healthcare disruption. His pharmaceutical company was built on a simple premise: show the cost, add a transparent markup, and publish it. So when he returned to his blog "Blog Maverick" last year with a post titled "A Few Words On Healthcare," he wasn't just offering commentary. He was expanding that same pricing philosophy to the entire $5 trillion U.S. heal ...

Q4/FY 2025 Financial Results & Business Update February 26, 2026 © Copyright 2026. All rights reserved. Mannkind Corporation. Cautionary Statement Statements in this presentation that are not statements of historical fact are forward-looking statements that involve risks and uncertainties. Words such as "believes", "anticipates", "plans", "expects", "intend", "will", "goal", "potential" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based up ...

Atai Life Sciences (NasdaqGM:ATAI) Update / briefing February 26, 2026 08:00 AM ET Company ParticipantsAndrew Tsai - Managing DirectorArabella Ng - Biotech Equity ResearchElemer Piros - Managing DirectorJason Awe - VP of Investor RelationsKevin Craig - Chief Medical OfficerPete Stavropoulos - Director and Biotech Equity ResearchSrini Rao - CEO and Co-founderConference Call ParticipantsAmi Fadia - Senior AnalystDuke Dales - AnalystEddie Hickman - VP and Senior Equity Research AnalystHarry Gillis - Senior Equ ...

Collegium Pharmaceutical (NasdaqGS:COLL) Q4 2025 Earnings call February 26, 2026 08:00 AM ET Speaker5Greetings! Welcome to the Collegium Pharmaceutical fourth quarter and full year 2025 earnings conference call. At this time, all participants are in listen-only mode. A question-and-answer session will follow the formal presentation. If anyone should require operator assistance during this conference call, please press star zero on your telephone keypad. Please note, this conference call is being recorded. I ...

Zai Lab (NasdaqGM:ZLAB) Q4 2025 Earnings call February 26, 2026 08:00 AM ET Speaker8Hello, ladies and gentlemen. Thank you for standing by, and welcome to Zai Lab's fourth quarter and full year 2025 financial results conference call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session, and instructions will follow at that time. As a reminder, today's call is being recorded. It's now my pleasure to turn the floor over to Christine Chiou, Senior Vice ...

Phathom Pharmaceuticals (NasdaqGS:PHAT) Q4 2025 Earnings call February 26, 2026 08:00 AM ET Speaker8Hello, and welcome to Phathom Pharmaceuticals' fourth quarter and full year 2025 earnings results call. At this time, all participants are in a listen-only mode. After the presentation, there will be a question-and-answer session. To ask a question, please press star one one on your telephone keypad. Please be advised that today's call is being recorded. With that, I would like to turn the call over to Eric S ...

Olema Pharmaceuticals (NasdaqGS:OLMA) FY Conference February 26, 2026 08:00 AM ET Company ParticipantsSean P.Bohen - President and CEOConference Call ParticipantsMatthew Biegler - Senior AnalystMatthew BieglerGood morning, everyone. Thanks for joining our healthcare conference. I'm Matt Biegler. I'm the covering analyst for Olema, and I'm really pleased to have President and CEO Sean Bohen with us today. Sean, pleasure as always. You know, I think a lot of people know the story, right? When it comes to the ...

SAN DIEGO, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Corcept Therapeutics Incorporation (NASDAQ: CORT) common stock between October 31, 2024 and December 30, 2025. Corcept is a pharmaceutical company focused on the development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol. For more information, s ...

BeOne Medicines (NasdaqGS:BGNE) Q4 2025 Earnings call February 26, 2026 08:00 AM ET Speaker10Good day, everyone. Welcome to BeOne Medicines Q4 and full year 2025 earnings call webcast. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. At this time, I would like to turn the call over to the company.Speaker3Hello and welcome. Thanks for joining us today. I'm Dan Maller, Head of Investor Relations at BeOne Medicines. Be ...